Navigation Links
Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Genentech, Inc. (NYSE:DNA) today announced updated results from a joint analysis of two Phase III clinical trials studying Herceptin(R) (trastuzumab) for the adjuvant treatment of HER2-positive breast cancer. Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) showed that, with median follow-up of nearly three years, the addition of Herceptin to standard adjuvant therapy significantly improved overall survival in women with HER2-positive, node-positive breast cancer, compared to patients who received standard adjuvant therapy alone. Herceptin (with chemotherapy) is the first and only HER2-targeted therapy to demonstrate an overall survival benefit in adjuvant breast cancer, based on these study results, and in first-line metastatic HER2-positive breast cancer.

"These findings show, when using Herceptin for the adjuvant treatment of women with HER2-positive, node-positive breast cancer, patients live longer," said Hal Barron, M.D., Genentech's senior vice president, Development and chief medical officer. "These data further reinforce the use of Herceptin and chemotherapy as the foundation of care for women with this aggressive form of the disease."

Edith Perez, M.D., director of Mayo Clinic's Multidisciplinary Breast Clinic in Jacksonville, Fla., presented these updated data from the joint analysis of NCCTG N9831 and NSABP B-31 (Abstract #512 -- Monday, June 4, 2007, 9 a.m. CDT) studying Herceptin in the adjuvant setting. Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment - surgery with or without radiation therapy - with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease.

These two randomized, controlled Phase III studies evaluated four cycles of doxorubicin and cyclophosphamide followed by paclitaxel, either every t
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
5. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
6. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
7. Media Advisory: ACC Updated Schedule
8. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
9. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
10. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
11. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
Post Your Comments:
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely eradicated ... generation ago are returning. Measles was declared eliminated in ... 2014 as of August 15—the highest incidence in 20 ... health department declared whooping cough a problem of ... getting sick and dying from these preventable diseases—in part ...
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... The Department of Justice, on behalf of the U.S. Food ... permanent injunction against generic drug manufacturer Ranbaxy in the ... filed against Ranbaxy Laboratories, Ltd., an Indian corporation; its ... Dale Adkisson, senior vice president, head of global quality, ...
... Fine Chemicals LLC (AFC), a wholly owned subsidiary of ... today that is has been granted Registration as a ... Agency (DEA). AFC has been involved in ... under a Researcher,s License from the DEA.  Recent facilities ...
Cached Medicine Technology:Department of Justice files consent decree of permanent injunction against Ranbaxy 2Department of Justice files consent decree of permanent injunction against Ranbaxy 3Department of Justice files consent decree of permanent injunction against Ranbaxy 4AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing 2AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing 3AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing 4
(Date:8/30/2014)... (PRWEB) August 30, 2014 One of the ... era is the gluten-free diet. Originally meant for sufferers of ... a catchall for people who are looking to get healthier ... not only is this kind of information erroneous, it also ... problems because of a drastic change in their food ...
(Date:8/30/2014)... 30, 2014 LiveStreamingFitness.com, a company dedicated to ... healthy lifestyle resources, is proud to announce it has been ... at home fitness solutions by ABC’s Good Morning America. ... on ABC’s Good Morning America, “Live Streaming Fitness is the ... your day by streamlining your workout…to boot camp at Life ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 “In 2013, a ... The Jones Firm says in a recently released article on ... person was injured in an auto accident every 12 minutes, ... minutes,” they continue. “Based on the 2013 statistics, between now ... vehicle collision.” , The threat of an auto accident is ...
(Date:8/30/2014)... Boston, MA (PRWEB) August 30, 2014 ... and nurse practitioner locum tenens company , announces ... open September 1, 2014. Barton Associates is headquartered in ... Enfield, CT; Keene, NH; and Jupiter, FL. ... response to the increasing demand for healthcare providers. The ...
(Date:8/30/2014)... The first multidisciplinary recommendations on the management of ... are published today in EP Europace . ... the European Heart Rhythm Association (EHRA), the Acute ... of Percutaneous Cardiovascular Interventions (EAPCI), all of the ... of the task force, said: "Sudden cardiac death ...
Breaking Medicine News(10 mins):Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:LiveStreamingFitness.com is New Trend In Fitness 2Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Barton Associates Announces New Office Location in Austin, TX 2Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2
... blood clot that develops deep in the vein. It can ... ,People who require prolonged bed rest are vulnerable ... patients in intensive care and patient on catheters are at ... in critically ill patients , a small pulmonary embolism, which ...
... high levels of amino acid are associated with an ... been // associated with an increased risk of heart ... to be associated with homocystinuria, a rare disease characterized ... high levels have also been found to be associated ...
... consisting of periods of growth (anagen), regression (catagen), ... activation of ?-catenin in // telogen-phase adult hair ... Scientists have discovered that the transient activation of ... growth. ,Previous work has implicated Wnt/?-catenin ...
... Not all vitamins may be good for you. A new ... antioxidant vitamins, such as // E, C and beta carotene, ... ,Some studies have shown that vitamin E prevented the ... cells. Thus, the liver destroyed fewer of the bad lipoproteins. ...
... new type of stent that releases medication appears safe ... heart disease patients, // a process known as restenosis. ... drug everolimus. The drug acts by inhibiting cell reproduction ... similar drug-eluting stents, the one used in this study ...
... a recent study neurosurgeons say they are now convinced ... ,Studies in the past have suggested wearing helmets during ... the risk of skull base and cervical-spine (or neck) ... findings prompted researchers to study whether helmets harm or ...
Cached Medicine News:Health News:New Hair in 15 Days Could Now Be A Possibility Say Researchers 2
... contains primers and a FAM-labeled probe that ... gene. In addition, this ASR contains primers, ... internal control sequence. This ASR requires an ... Red reporter dyes such as the Cepheid ...
...
Reptilase-Time from Bothrops atrox...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Medicine Products: